Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients

A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer

This study is using the combination of radiation and antiangiogenic agents (agents that destroy existing blood vessels) seems to be an approach to tumor cure.

The combination of ionizing radiation and antiangiogenic agents seems to be a counterintuitive approach to tumor cure because oxygen is a potent radiosensitizer and a reduction in oxygen concentration would be expected following a reduction in tumor vasculature after antiangiogenic treatment.

Inclusion Criteria:

• Minimum 2 week course of radiation therapy
• Solid tumors of the central nervous system, head and neck, thorax, and pelvis

Exclusion Criteria:

• Major surgery or radiation therapy within 4 weeks starting study treatment
• Grade 3 hemorrhage within 4 weeks